Switch to: References

Add citations

You must login to add citations.
  1. Ethical issues at the university-industry interface: A way forward?G. R. Evans & D. E. Packham - 2003 - Science and Engineering Ethics 9 (1):3-16.
    This paper forms an introduction to this issue, the contents of which arose directly or indirectly from a conference in May 2001 on Corruption of scientific integrity? — The commercialisation of academic science. The introduction, in recent decades, of business culture and values into universities and research institutions is incompatible with the openness which scientific and all academic pursuit traditionally require. It has given rise to a web of problems over intellectual property and conflict of interest which has even led (...)
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • Ethical issues at the university-industry interface: A way forward? [REVIEW]Professor G. R. Evans & D. E. Packham - 2003 - Science and Engineering Ethics 9 (1):3-16.
    This paper forms an introduction to this issue, the contents of which arose directly or indirectly from a conference in May 2001 on Corruption of scientific integrity? — The commercialisation of academic science. The introduction, in recent decades, of business culture and values into universities and research institutions is incompatible with the openness which scientific and all academic pursuit traditionally require. It has given rise to a web of problems over intellectual property and conflict of interest which has even led (...)
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • G.A.T.s. And universities: Implications for research.David E. Packham - 2003 - Science and Engineering Ethics 9 (1):85-100.
    The likely impact of applying the General Agreement on Trade in Services (GATS) to higher education are examined. GATS aims to “open up” services to competition: no preference can be shown to national or government providers. The consequences for teaching are likely to be that private companies, with degree-awarding powers, would be eligible for the same subsidies as public providers. Appealing to the inadequate recently introduced “benchmark” statements as proof of quality, they would provide a “bare bones” service at lower (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Patients' health or company profits? The commercialisation of academic research.Nancy F. Olivieri - 2003 - Science and Engineering Ethics 9 (1):29-41.
    This paper is a personal account of the events associated with the author’s work at the University of Toronto’s Hospital for Sick Children on a drug, deferiprone, for the treatment of thalassaemia. Trials of the drug were sponsored by the Canadian Medical Research Council and a drug company which would have been able, had the trials been successful, to seek regulatory approval to market the drug. When evidence emerged that deferiprone might be inadequately effective in a substantial proportion of patients, (...)
    Download  
     
    Export citation  
     
    Bookmark   12 citations